Key facts
- Anthropic has established a physical laboratory for biology experiments.
- The company aims to develop treatments for rare diseases.
- Anthropic's Claude AI now leads 26% of its AI R&D, up from 1% in March.
- AI collaborates on over 90% of Anthropic's research and development.
- Anthropic's head of life sciences, Eric Kauderer-Abrams, confirmed the wet lab.
- The company is not currently running clinical trials.
Anthropic, the artificial intelligence startup, has established a physical laboratory for biology experiments as it expands its ambitions into drug science. The company aims to develop treatments for rare diseases, moving beyond purely computer-based evaluations. This initiative aligns with Anthropic's broader goal of using AI for global benefit, particularly in life sciences.
Eric Kauderer-Abrams, Anthropic's head of life sciences, confirmed the existence of the wet lab in San Francisco, stating that real lab work is currently being conducted. He described the approach as typical of biotech companies, involving both in-house facilities and external partnerships. A spokesperson later clarified that the lab is not specifically for drug discovery.
The move represents a step toward Anthropic's ambition to tackle diseases that the pharmaceutical industry may be neglecting. CEO Dario Amodei is personally motivated by the mission, having experienced the loss of a parent to a disease for which a cure was later found. Anthropic believes AI offers the biggest opportunity to accelerate drug development.
Anthropic is exploring how its Claude AI can direct robotic units for scientific experiments with limited human intervention, though human oversight remains essential for safety. Kauderer-Abrams noted that the company is in the early stages of using AI to automate lab work, which could significantly speed up various processes.
This expansion into life sciences comes as Anthropic navigates public fears about AI's potential risks, including concerns about AI leading to human extinction and potential misuse for biological weapons development. Amodei has also called for a slowdown in AI development due to catastrophic damage risks from future, more capable AI systems. Anthropic is reportedly preparing for a potential $2 trillion IPO to fund further AI development.
Kauderer-Abrams stated that Anthropic is balancing the goal of improving AI for medicine development with careful deployment to limit risks. The company previously announced its intention to run drug programs for financially unattractive areas and launched software called Claude Science. It also added Novartis CEO Vas Narasimhan to its board and acquired Coefficient Bio for approximately $400 million in stock to aid in building drug development tools.
Anthropic is enhancing its in-house lab capabilities for speed and direct experience in biology, while also outsourcing work when efficient. The company has posted job openings for roles related to procurement, protein and nucleic acid characterization, and accelerating progress in life sciences. Life sciences is already a significant investment area for Anthropic in terms of headcount and resources.